Sara Coburn
Nurse Practitioner · Fort Wayne, INNPI 1861115750
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 522 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,519, more than ten times the $73 reported in 2022. Among nurse practitioner clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 522 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- Alkermes, Inc.$810
- E.r. Squibb & Sons, L.L.C.$607
- plus $3K from 17 others
What the payments were for
- Food & beverage$8,72596%
- Education$3184%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 126 | $1,567 |
| Teva Pharmaceuticals USA, Inc. | 42 | $1,033 |
| Otsuka America Pharmaceutical, Inc. | 44 | $1,031 |
| Lundbeck LLC | 73 | $1,020 |
| Alkermes, Inc. | 40 | $810 |
| E.r. Squibb & Sons, L.L.C. | 36 | $607 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $494 |
| Corium, LLC | 27 | $397 |
| Neurocrine Biosciences, Inc. | 22 | $382 |
| Supernus Pharmaceuticals, Inc. | 16 | $284 |
| Axsome Therapeutics, Inc. | 9 | $268 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $248 |
| Johnson & Johnson | 7 | $200 |
| Tris Pharma Inc | 11 | $181 |
| Indivior Inc. | 9 | $168 |
| Biogen | 5 | $115 |
| Ironshore Pharmaceuticals Inc. | 4 | $86 |
| Inspire Medical Systems, Inc. | 3 | $66 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$249
- INVEGA SUSTENNA$142
- REXULTI$125
- Auvelity$120
- COBENFY$102
How this compares
$9,043 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 28 | $347,250 |
| Invega SustennaPaliperidone Palmitate | 58 | $180,005 |
| VraylarCariprazine Hcl | 53 | $91,160 |
| Abilify AsimtufiiAripiprazole | 16 | $87,667 |
| RexultiBrexpiprazole | 28 | $40,616 |
| TrintellixVortioxetine Hydrobromide | 28 | $28,807 |
| Abilify MaintenaAripiprazole | 11 | $27,862 |
| BelsomraSuvorexant | 20 | $24,428 |
| Aripiprazole | 65 | $9,603 |
| Paliperidone ErPaliperidone | 19 | $8,844 |
| Olanzapine | 63 | $7,325 |
| Bupropion XlBupropion Hcl | 85 | $4,190 |
| Clozapine | 27 | $2,898 |
| Oxcarbazepine | 28 | $2,476 |
| Ziprasidone Hcl | 21 | $2,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,033 | $347,25028 claims |
| Johnson & JohnsonInvega Sustenna | $200 | $180,00558 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti, Abilify Maintena | $1,031 | $156,14455 claims |
| AbbVieVraylar | $1,567 | $91,16053 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $248 | $28,80728 claims |
| MerckBelsomra | $13 | $24,42820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Fort Wayne
- Sean GoddardFort Wayne$180K
- Kristine TaylorFort Wayne$69K
- Mary BullisFort Wayne$27K
- Nathan MinerFort Wayne$21K
- Joel NagelFort Wayne$20K
- Gabriela NorthFort Wayne$18K
- Karen LothamerFort Wayne$12K
- Pamela ShodaFort Wayne$11K
- Marlise FletterFort Wayne$9K
- Kristi OrbaughIndianapolis$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.